Guides
How to read an FDA drug label (prescribing information)
How to read prescribing information on an FDA drug label, section by section: Highlights, the boxed warning, indications, dosing, warnings and clinical studies.
By the All In Biotech editorial team · Published November 18, 2026 · 6 min read
An FDA drug label, formally the prescribing information and often called the package insert, is the document FDA approves to describe a drug's approved uses, dosing, risks and evidence. Most current labels start with a one-page Highlights summary, followed by the full prescribing information in 17 numbered sections. Read the Highlights and any boxed warning first, then go to the numbered section that answers your question.
This guide walks through each part. It explains what the sections mean, not how to use any drug: decisions about treatment belong with a clinician.
Two label formats
FDA's Physician Labeling Rule (PLR), which took effect in 2006, set the current format: Highlights, a table of contents and the full prescribing information in numbered sections. It applies to new applications and, on a phased schedule, to drugs approved in the five years before it took effect. Some older drugs still use the earlier "non-PLR" format, with unnumbered sections such as Description, Clinical Pharmacology, Indications, Contraindications, Warnings and Precautions. FDA encourages sponsors to convert those labels, but many older generics and brands still carry them.
FDA explains both formats in its labeling FAQ and on its prescribing information resources page. The rest of this guide follows the PLR format.
Highlights of prescribing information
Highlights is a short summary, usually about half a page, at the top of the label. It includes:
- the product title and the year of initial US approval,
- the boxed warning in brief, if there is one,
- Recent Major Changes, listing sections changed in the last year or so, with dates,
- short versions of the indications, dosing, dosage forms, contraindications, warnings and common adverse reactions,
- the revision date ("Revised: month/year").
Highlights itself says it does not include all the information needed to use the drug safely and effectively. Treat it as a map of the full label, not a substitute for it.
The revision date matters. Labels change when FDA approves a new use, adds a warning or updates dosing. If you are citing a label, note which version you read. Each drug page on this site states the date of the label in effect.
Boxed warning
A boxed warning appears in a black border at the top of the full prescribing information. FDA requires one for serious or life-threatening risks that should shape whether and how a drug is prescribed. Ozempic's label, for example, carries a boxed warning about the risk of thyroid C-cell tumors.
A boxed warning does not mean a drug is unsafe for everyone, or that it is less safe than a drug without one. It means FDA judged the risk important enough to place first. The details are usually expanded in Section 5.
Sections 1 to 4: what it is for and how it is given
1 Indications and Usage. The approved uses. Each indication is written precisely: the disease, the patient group and any condition on prior treatment, combination use or biomarker. A "Limitations of Use" statement may follow, saying what the drug has not been shown to do or should not be used for. This is the section that defines "FDA-approved for". The condition search on this site matches drugs on this section, as explained in how to find every FDA-approved drug for a condition.
2 Dosage and Administration. Recommended doses, titration, how to give the drug, and adjustments for kidney or liver impairment, drug interactions or side effects. Dose tables here are often the most-read part of the label.
3 Dosage Forms and Strengths. The tablets, vials, pens or other forms available, with strengths.
4 Contraindications. Situations in which the drug should not be used because the risk clearly outweighs any benefit. If there are none, the label says "None."
Sections 5 to 7: risks
5 Warnings and Precautions. The clinically significant risks, each with a short description, how to monitor for it and what to do. Boxed warning topics are covered here in more detail. This section is usually longer than the boxed warning and covers more risks.
6 Adverse Reactions. Side effects seen in clinical trials, usually in tables comparing the drug with placebo or a comparator, followed by reactions reported after approval. Trial rates come from controlled studies. Postmarketing reports come from voluntary reporting, and the label usually says their frequency cannot be reliably estimated.
7 Drug Interactions. Drugs and other substances that change this drug's effect, or whose effect this drug changes, with recommended actions.
For reports that reach FDA after approval, see how to search FAERS. Report counts there are not rates, and they are not part of the label.
Section 8: specific populations
Section 8 covers groups who may respond differently:
- 8.1 Pregnancy and 8.2 Lactation: under the Pregnancy and Lactation Labeling Rule, effective June 30, 2015, these subsections give a narrative risk summary and supporting data in place of the old letter categories (A, B, C, D and X). Labels for drugs approved before the rule took effect were converted on a phased schedule, so some older labels may still describe pregnancy data in a different layout.
- 8.3 Females and Males of Reproductive Potential: pregnancy testing, contraception and fertility information, when relevant.
- 8.4 Pediatric Use and 8.5 Geriatric Use: what is known about children and older adults, including whether safety and effectiveness have been established.
- Further subsections, when included, cover kidney impairment, liver impairment and other groups.
FDA describes the rule on its pregnancy and lactation labeling page.
Sections 9 to 13: abuse, overdose and science
9 Drug Abuse and Dependence lists any controlled substance schedule and abuse, dependence or withdrawal risks. 10 Overdosage describes signs of overdose and management. 11 Description gives the chemical or biological description and inactive ingredients. 12 Clinical Pharmacology covers mechanism of action, pharmacodynamics and pharmacokinetics, such as half-life and how the drug is cleared. 13 Nonclinical Toxicology summarizes animal studies of cancer risk, mutation and fertility.
Sections 12 and 13 are technical, but 12 often explains why a dose adjustment or interaction in Sections 2 and 7 exists.
Section 14: clinical studies
Section 14 summarizes the trials that support each indication: design, patient population, endpoints and main results, often with tables or survival curves. It is the label's evidence section, written and reviewed under FDA rules.
Reading it alongside Section 1 shows what each approval was based on. An accelerated approval, for example, is usually based on a surrogate endpoint such as tumor response, and the label notes that continued approval may depend on a confirmatory trial. For the programs behind those approvals, see breakthrough, fast track, accelerated approval and priority review compared.
To find the registered trials themselves, use this site's trial search or ClinicalTrials.gov. Each drug page also lists trials naming its ingredient.
Sections 15 to 17 and patient labeling
15 References is included only when needed. 16 How Supplied/Storage and Handling gives package sizes, identifying codes (NDC numbers) and storage conditions. 17 Patient Counseling Information tells the prescriber what to discuss with patients.
After the prescribing information, many labels include FDA-approved patient labeling: a Medication Guide (required for certain drugs with serious risks), Patient Information or Instructions for Use. These are written in plain language and are the right starting point for patients.
Where to read a label
- DailyMed, run by the National Library of Medicine, has the current labels submitted to FDA, searchable by name, with past versions.
- Drugs@FDA holds the labels FDA approved with each action, linked from the approval history.
- On this site, each drug page shows the current label's approved uses and boxed warning, the approval history with FDA's letters and labels, registered trials, adverse event reports, recalls, shortages and Medicare spending in one place.
Generic drugs carry labels that match their reference brand, with some permitted differences. The brand label is usually the best place to read the full evidence.
Frequently asked questions
- What is a boxed warning on a drug label?
- A boxed warning, often called a black box warning, is a bordered statement at the top of the prescribing information that FDA requires for serious or life-threatening risks.
- Where is the approved use listed on a drug label?
- Section 1, Indications and Usage, lists every use FDA has approved, often with limits on age, disease stage or prior treatment.
- Where can I read the current label for a drug?
- DailyMed from the National Library of Medicine carries the current labels submitted to FDA, and Drugs@FDA holds the labels FDA approved with each action.
- Is the prescribing information written for patients?
- No. It is written for health care professionals, and many drugs also have a Medication Guide or Patient Information leaflet in plain language.
For information only, not medical, legal or investment advice. Facts about FDA and CMS programs are current as of the publication date; check the linked official source for changes.